Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talampanel in Recurrent High-Grade Gliomas
NCT00064363Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of talampanel in glioma (3 arms), sponsored by National Institutes of Health. Primary endpoint: Progression-Free Survival at 6 months. Started Jun 2003; status: completed.
02
Drugs
talampanel
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00064363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064363.